ArticleAntibiotics (Basel, Switzerland)2024
Antibiofilm and Immune-Modulatory Activity of Cannabidiol and Cannabigerol in Oral Environments-In Vitro Study.
Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Osteogenic Response of Dental Pulp Stem Cells (DPSCs) to an Alginate/Chitosan/Cannabidiol Hydrogel.Gels (Basel, Switzerland) · 2026Article
- Therapeutic Potential of Cannabidiol in Dysbiosis-Related Oral Biofilm Diseases: Antibiofilm, Antivirulence and Host Response Evidence.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Combining Diclofenac and Cannabidiol to Enhance the Antibacterial Capacity of Nonantibiotic Drugs Through Potentiation.International journal of molecular sciences · 2026Article
- Probiotic-Plant Bioactive Synergy in Gut Health: Mechanisms, Antimicrobial Activity, and Translational Challenges.Nutrients · 2026Review
- Cannabidiol in Periodontal Therapy-Is There Hope or Just a Bias? A Systematic Review.Biomedicines · 2026Review
- Efficacy of Cannabidiol in Reducing Virulence ofInternational journal of molecular sciences · 2026Article
- Evaluation of the antimicrobial effect of cannabidiol (CBD) in a multispecies subgingival biofilm model.Journal of oral microbiology · 2026Article
- Potential Antimicrobial Use of Cannabidiol in Dentistry: A Scoping Review.Dentistry journal · 2025Review
- Potential of Cannabidiol (CBD) to overcome extensively drug-resistant Acinetobacter baumannii.BMC complementary medicine and therapies · 2025Article
- Antimicrobial Potential of Cannabinoids: A Scoping Review of the Past 5 Years.Microorganisms · 2025Review
- Cannabidiol (CBD) Acts as an Antioxidant onAntibiotics (Basel, Switzerland) · 2025Article
- Identification of cannabinoid-sensitive and -resistant oral bacteria.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the in vitro antimicrobial and antibiofilm properties and the immune modulatory activity of cannabidiol (CBD) and cannabigerol (CBG) on oral bacteria and periodontal ligament fibroblasts (PLF).
methodsCytotoxicity was assessed by propidium iodide flow cytometry on fibroblasts derived from the periodontal ligament. The minimum inhibitory concentration (MIC) of CBD and CBG for
resultsCBD-treated cell viability was greater than 95%, and for CBG, it was higher than 88%. MIC for
conclusionBoth CBG and CBD inhibit
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.